← Home
📢 Press Releases
| Date | Press release |
|---|---|
| 2026-01-06 18:30:00 | Astellas To Present At 44th Annual J.p. Morgan Healthcare Conference Tokyo, jan. 6, 2026 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, ’astellas’) today announced it will present at the 44th annual j.p. morgan healthcare conference, taking place january 12-15, 2026, in san francisco, calif. |
| 2025-12-11 07:30:00 | Autobahn Labs Forms Strategic Partnership With Astellas To Accelerate Academic Discoveries Into New Medicines Palo alto, calif., dec. 11, 2025 (globe newswire) -- autobahn labs (“autobahn”), a venture studio focused on transforming high-potential academic science into investable drug discovery and development programs, announced today a strategic partnership with global life sciences company astellas pharma inc. (“astellas”). |
| 2025-12-10 18:30:00 | Astellas To Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio At 2026 Asco Gi Cancers Symposium - data reflect new insights and precision oncology advancements in portfolio and pipeline - - cohort results from phase 2 ilustro study evaluating a zolbetuximab triplet combination regimen in first-line advanced gastric and gastroesophageal junction (gej) cancer featured in late-breaking oral presentation - tokyo , dec. 10, 2025 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, ’astellas’) today announced it will present data on potential treatments for pancreatic and gastric/gastroesophageal junction (g/gej) cancer at the 2026 american society of clinical oncology (asco) gastrointestinal (gi) cancers symposium taking place january 8-10, 2026 in san francisco, california. highlights include a late-breaking oral presentation of cohort results from the phase 2 ilustro study of first-line zolbetuximab in combination with chemotherapy and immunotherapy in claudin 18.2-positive, her2-negative, locally advanced or metastatic g/gej cancer, as well as new phase 1 data from asp3082 (setidegrasib), an investigational kras g12d targeted protein degrader, in pancreatic cancer. |
| 2025-12-05 08:00:00 | Astellas To Present New Data On Xospata™ (gilteritinib) Across The Flt3m+ Aml Disease Continuum At Ash 2025 Annual Meeting - presentations include pooled post-hoc analysis of the phase 3 admiral and commodore data on post-transplant gilteritinib resumption in relapsed or refractory flt3m+ aml - - findings from the phase 3 morpho trial in the post-transplant maintenance setting and phase 1/2 viceroy trial in newly diagnosed disease highlight how treatment timing, sequencing and combination approaches may influence outcomes - tokyo , dec. 5, 2025 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, ’astellas’) today announced that new data evaluating xospata™ (gilteritinib) across fms-like tyrosine kinase 3 mutation-positive (flt3m+) acute myeloid leukemia (aml), including in relapsed or refractory (r/r), newly diagnosed and post-transplant maintenance settings, will be presented at the upcoming american society of hematology (ash) annual meeting taking place from 6-9 december 2025 in orlando, fla. through ongoing research with gilteritinib, astellas is advancing the science of flt3m+ aml and generating new evidence across the disease stages, to help improve long-term outcomes for people diagnosed with flt3m+ aml. |
| 2025-10-23 08:00:00 | Astellas And The Internet’s Favorite Grandma, Barbara ’babs’ Costello, Partner To Encourage Others To Get Ahead Of Geographic Atrophy (ga) Babs is sharing her family’s history with progressive retinal disease ga, the advanced form of dry age-related macular degeneration (amd), is a serious condition that may lead to irreversible vision loss1 northbrook, ill. , oct. 23, 2025 /prnewswire/ -- astellas pharma us inc. (tse: 4503, head of us commercial: michael petroutsas, ’astellas’), maker of izervay™ (avacincaptad pegol intravitreal solution), today announced a partnership with beloved grandmother and content creator, barbara ’babs’ costello (@brunchwithbabs), to challenge the misconception that vision changes are simply a normal part of aging, while raising awareness about the signs, risk factors and treatment of geographic atrophy (ga), the advanced form of dry age-related macular degeneration (amd). |
| 2025-10-22 08:00:00 |
|
| 2025-10-14 20:00:00 |
|
| 2025-10-08 19:30:00 |
|
| 2025-09-29 02:00:00 |
|
| 2025-07-17 00:00:00 |
|
| 2025-06-13 01:10:00 |
|
| 2025-05-29 20:15:00 |
|
| 2025-05-28 10:00:00 |
|
| 2025-05-21 11:00:00 |
|
| 2025-05-01 09:00:00 |
|
📰 Browse additional press releases for Astellas Pharma!
Sign up for free or log in🎁 Free download! "The Checklist Value Investor — A Smarter Way to Pick Stocks"